Novavax Inc

Novavax trades at a remarkably compressed 3.61 P/E ratio, suggesting deep market skepticism about earnings sustainability or future growth. With market cap of just $1.7B and 30.28% short interest, the stock carries significant squeeze potential if sentiment shifts, though the elevated RSI of 61.5 hints at near-term overbought conditions. The biotech's valuation discount could reflect legitimate concerns about pipeline execution or revenue durability, or it could represent a genuine opportunity if the company demonstrates stronger-than-expected clinical or commercial progress. The elevated short position creates a precarious setup where any positive catalyst could trigger violent covering rallies, but the RSI suggests momentum may be running ahead of fundamentals.